BioSpace News Archive

Altimmune, Inc. today announced oral presentations on pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH, at the American Diabetes Association’s (ADA) 84th Scientific Sessions, to be held in Orlando, FL from June 21-24, 2024.

MilliporeSigma and The Michael J. Fox Foundation for Parkinson’s Research (MJFF), are advancing research aimed at slowing progression of Parkinson’s disease (PD).

Aytu BioPharma, Inc. today announced the successful refinancing of its existing term loan and extension of its revolving credit facility on more favorable terms to the Company.

Takeda (TSE:4502/NYSE:TAK) today announced data from the Phase 3 ADVANCE-CIDP 3 clinical trial, a long-term extension study evaluating the safety and efficacy of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics technology, filed for voluntary chapter 11 protection in the U.S. Bankruptcy Court for the District of Delaware.

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, is honored to announce it has been named to Inc. Magazine’s Best Workplaces list.

Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) today announced that Amit Etkin, M.D., Ph.D., founder and CEO, was named an Entrepreneur Of The Year® 2024 Bay Area Award finalist by EY.

Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” and the “Company”) today announced that the Company will host a teleconference to update investors and other stakeholders in the Company on a number of business and financial topics.

The Foundation for the National Institutes of Health will award the 2024 Charles A. Sanders, MD, Partnership Award to the National Institutes of Health’s National Institute of Neurological Disorders and Stroke, AbbVie, and Robert and Sarah Newcomb.

Cerevance will deliver a poster presentation at the upcoming Federation of European Neuroscience Societies (FENS) Forum 2024, taking place in Vienna, Austria, from June 25 – 29, 2024.